RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021) Save
RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
- Study of 435 #SLE pts seen during the pandemic. Comparing those seen F2F vs telemedicine, there was no significant difference in SLE disease activity (by SLEDAI-2K) or SLE flare rates or steroid prescribing between visit types https://bit.ly/39wWoQ6
- Encouraging DBRPCT of Rituximab in #PMR: 116 screened, 49 enrolled, 47 completed: 23 on RTX vs 24 on PBO. Steroid-free remission at 21 wks seen with 11/23 (48%) RTX pts vs 5/24 (21%) on PBO (p=0·049). Infusion Rxns: 10 RTX vs 3 PBO); 1 SAE (PE) on RTX https://bit.ly/3lSI0rj
- Pregnancies exposed to ixekizumab (from Eli Lilly Global Safety Database) found 193 pts with psoriasis, PsA, or axSpA who were IXE exposed. Live births reported for 53.8 and 61.1% of known outcomes. No congenital malformations seen. https://t.co/M1rvCH81hT
- FDA approves Jakafi for chronic GVHD. Ruxolitinib (Jakafi, Incyte), an oral Janus kinase 1/2 inhibitor, previously received approval for treatment of patients aged 12 years or older with steroid-refractory acute GVHD. https://t.co/isItDebNZ8
- Retrosp. review of 10–24 yr olds w/ newly Dx #SLE shows 78% given steroid-sparing DMARDs by year 1; Most (69%) given HCQ & fewer (34%) given other immunosuppressants. Adults less likely to recv immDMARDs @1 yr https://t.co/aLi6FXlMd3
- Case controlled study shows CPPD pts have no higher risk for MACE. 23,124 CPPD vs 86,629 non-CPPD, w/ >250,000 Pt-Yrs FU. CPPD MACE risk not increased (HR 0.98), but there was incr risk of MI, CVA & acute coronary syndr. https://t.co/pgmZBxTg9O
- Trade names: Generic PFIZER = Comirnaty; MODERNA= Spikevax Moderna; J&J (pending) https://t.co/MM7XiSCczl
- Prospective study of 77 RA patients in remission --> vax w/ BNT162b2 (BioNTech-Pfizer) (w/ temp D/C of DMARDs per ACR) found a vaccine-related flare rate of 7.8% (6 pts) w/ 5/6 flares after 2nd dose (2.6 days), resolved w/in 2 wks https://t.co/YOL3YVS2ne
- Dr. Calabrese shares his Delta COVID-19 breakthrough story on the blog today. https://t.co/timjB2YPys
- BMJ Breakthrough infections from UK QResarch database: Among 6.95 million vaccinated, 74.1% recv two vaccine doses, there were 2031 covid-19 deaths & 1929 hosp admissions; ~4.0% deaths & admissions were >14 days after 2nd dose
- Addendum: COVID deaths increased w/ age, deprivation, male, Indian & Pakistanis. Highest risk w/ Down’s syndr (HR 12.7), renal transplant (8.1), sickle cell (7.7), Nursing home (4.1), chemotherapy (4.3), HIV/AIDS (3.3), liver cirrhosis (3), CNS dz (2.6)
- Addendum: Other conditions w/ a 1.2-2 fold higher risk of COVID death (admission) were CKD, hematologic cancer, epilepsy, COPD, CVD, stroke, atrial fibrillation, CHF, thromboembolism, PVD, type 2 diabetes. https://t.co/bbDsb1zLhX
- Claims case-controlled study shows statin use does not increase the risk of #RA - 32,726 RA and matched controls ; statin use (34 vs 32%) slightly increased RA risk (OR 1.12, 1.06–1.18), but signif lost after correcting for hyperlipidemia https://t.co/EcTlyE1MPx
- High Comorbidity Rates with Inclusion Body Myositis
- Guselkumab Treats Axial Disease in Psoriatic Arthritis
- 11 Drugs That Cause Arthritis https://rheumnow.com/news/11-drugs-cause-arthritis
- Viewer Question – A positive anti ds DNA in the absence of clinical evidence of lupus?
More ACR Coverage:
ADD THE FIRST COMMENT
Disclosures
Disclosures
The author has received compensation as an advisor or consultant on this subject

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.